Cancer Genetics Inc

Cancer Genetics — Q1 2018 Earnings Presentation

11 slides from Cancer Genetics's earnings presentation, May 15, 2018

  1. Slide 1: Q1 2018 Earnings Report & Company Updates

    CANCER GENETICS INCORPORATED Empowering Personalized Cancer Treatment / i i webcast link: & i “ http://public. viavid.comlindex.php?id=129776 . Bs jis , Q1 2018 Earnings Report & Comp: Updates Tuesday — May 15, 2018 | 8:30am Eastern

  2. Slide 2: Forward-Looking Statements

    ‘p.2] Gi Forward-Looking Statements These slides may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in revenues, margins, research, technology, clinic

  3. Slide 3: Everything We Do Is Focused on 1 Key Idea

    EVERYTHING WE DO IS FOCUSED ON 1 KEY IDEA... ...DELIVER INNOVATION & PATIENT VALUE BY PROVIDING THE MOST COMPREHENSIVE CAPABILITIES FOR PRECISION ONCOLOGY DEVELOPMENT.

  4. Slide 4: Revenue & Growth Highlights

    Gi Revenue & Growth Highlights p.4 | Q1 REVENUE FULL YEAR REVENUE ‘Amounts in $ milions Pa ‘Amounts in $ millions $29.0M 5-Year CAGR A1W% -- 6.1m - Q12014 § Q12015 Q12016 Qi2017 Qi 2018 2014 2015 2016 2017 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2018 Earnings Call

  5. Slide 5: Revenues by Market & Customer Category

    Gi Revenues by Market & Customer Category Pp. | $3.7M || BIOPHARMA SERVICES = Supports 241 clinical trials and studies focused on Solid Tumor and Blood Cancers, including 59 for immuno-oncology indications. CLINICAL SERVICES = Over 10,300 tests performed in Q1 2018. Comprehensive test portfolio incl

  6. Slide 6: Q1 2018 and Recent Operational Highlights

    Gi Q1 2018 and Recent Operational Highlights p.6] = Received special 510(k) clearance from the FDA for the Tissue of Origin (TOO®) test to identify tumor origin and differentiate between metastatic, poorly differentiated, or undifferentiated cancers. =» Completed sale of wholly-owned subsidiary BioS

  7. Slide 7: Q1 2018 Financial Highlights

    Gi Q1 2018 Financial Highlights p.7 | » Revenues of $7.7 million, 10% increase or $0.7 million over $7.0 million in Q1 2017. + Biopharma Services revenue totaled $3.7 million flat compared to $3.7 million during Q1 2017. + Clinical Services revenue totaled $2.3 million compared to $3 million during

  8. Slide 8: Summary Statement of Operations

    Summary Statement of Operations p.8 Income Statement Items ‘65 in thousanas) Q1 2017 Q4 2017 Q1 2018 Revenue $6,966 $7,523 $7,667 Gross Profit $2,757 $2,284 $2,585 Gross Margin (%) 40% 30% 34% Research & Development (R&D) $1,110 $1,709 $681 Sales & Marketing (S&M) $974 $1,553 $1,591 General & Admini

  9. Slide 9: Biotech and Pharma Highlights: Strong Year over Year & Quarterly Progress

    Biotech and Pharma Highlights: Gi Strong Year over Year & Quarterly Progress p.9] TOTAL ACTIVE PROJECTS 420 ACTIVE I/O PROJECTS BOOKINGS TO BILLING RATIO 101 : 2.2 io 297 308 Une 88 i : 300 z 80 42 eo 2 1.2 250 73 36 a 60 200 08 150 _ 140 224 241 40 32 06 52 ) 04 i |_| * | a7 50 0 o Q1 2017 Q4 2017

  10. Slide 10: Industry Leading Capabilities in Expanding Field of Immuno-Oncology

    p.10) Industry Leading Capabilities in Expanding G Field of Immuno-Oncology AntigenID™ Launched Neoantigen Identification Service to Accelerate Immuno-Oncology Drug NGS: Exome / Identification, Development and Pathology W544 ‘Neoantigen Repurposing i Validation _ i Identity Somatic + Based on neoant

  11. Slide 11: Cancer Genetics Incorporated - www.cgix.com

    CANCER c & IX WWW.CGIX.COM Cs GENETICS Namnagy as INCORPORATED LISTED WWW.CANCERGENETICS.COM

Cancer Genetics — Q1 2018 Earnings Presentation on 6ix